Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.

Abstract

OBJECTIVE The authors compared the efficacy of standard-of-care treatment plus intranasal esketamine or placebo for rapid reduction of symptoms of major depression, including suicidality, among individuals at imminent suicide risk. METHOD In a double-blind, multicenter, proof-of-concept study, 68 participants were randomly assigned to receive esketamine… (More)
DOI: 10.1176/appi.ajp.2018.17060720

Topics

  • Blog articles referencing this paper

  • Presentations referencing similar topics